New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
The first oral rescue therapy for acute attacks is on the horizon.
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.